| 1 |
33610123 | Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. | 2021 Apr |
1 |
| 2 |
31345267 | A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. | 2019 Jul 25 |
1 |
| 3 |
29274100 | Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer. | 2018 Apr |
1 |
| 4 |
27943222 | Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. | 2017 Jul |
1 |
| 5 |
28213941 | Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer. | 2017 Aug |
1 |
| 6 |
28339098 | Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. | 2017 Jul 15 |
1 |
| 7 |
26841902 | A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. | 2016 Apr |
1 |
| 8 |
27025186 | Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. | 2016 Mar 12 |
1 |
| 9 |
25329007 | A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. | 2015 Jul |
2 |
| 10 |
25895616 | A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. | 2015 Jul |
1 |
| 11 |
26082895 | CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. | 2015 |
1 |
| 12 |
26474517 | Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. | 2015 Nov |
1 |
| 13 |
24360368 | Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. | 2014 Mar |
1 |
| 14 |
24508126 | Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. | 2014 Apr |
1 |
| 15 |
25218906 | Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. | 2014 Oct |
1 |
| 16 |
19755510 | Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. | 2009 Sep |
3 |
| 17 |
19826113 | Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. | 2009 Nov 20 |
1 |
| 18 |
18520296 | The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. | 2008 Jun |
2 |
| 19 |
17458505 | Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). | 2007 Oct |
1 |
| 20 |
17671152 | Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. | 2007 Aug 1 |
1 |